透明质酸酶、喜辽妥对长春瑞滨外渗性大鼠皮肤损伤的疗效

目的:探讨透明质酸酶局部注射、喜辽妥软膏外涂对长春瑞滨外渗性大鼠皮肤损伤的防治效果。方法:在48只SD大鼠双后肢制作长春瑞滨血管外渗模型。随机分为6组,分别给予透明质酸酶局部注射、喜辽妥软膏外涂、透明质酸酶局部注射联合喜疗妥软膏外涂、生理盐水局部注射、生理盐水外涂以及模型对照组(不进行任何防治措施)。观察各组大鼠1d、4d、8 d、12d、18d、24d、30d的损伤面积和损伤愈合时间。结果:透明质酸酶局部注射组至30d损伤已痊愈,其1d、4d、8d、12d、18d、24d损伤面积均显著低于喜辽妥软膏外涂组、透明质酸酶局部注射联合喜辽妥软膏外涂组、生理盐水局部注射组、生理盐水外涂组和模型对照组(P<0.05);其损伤愈合时间为(21.9±3.0)d,也显著低于其他5组[(28.8±3.5)d、(28.0±2.9) d、(28.6±4.1)d、(29.8±2.6)d和(30.6±3.0)d,P<0.01]。结论:单用透明质酸酶局部注射对长春瑞滨外渗性损伤具有较好的疗效,而喜辽妥软膏外涂无效,联合用药未能提高疗效。     

几丁糖、透明质酸酶治疗多西紫杉醇外渗性大鼠皮肤损伤

背景与目的:多西紫杉醇外渗至周围组织可导致严重皮肤损伤,目前还没有公认的治疗指南.本研究旨在探讨单用或联合局部外涂几丁糖、注射透明质酸酶对多西紫杉醇大鼠外渗性皮肤损伤的疗效.方法:在30只SD大鼠双后肢建立多西紫杉醇血管外渗模型.随机分为6组,分别给局部外涂几丁糖、局部注射透明质酸酶、局部注射透明质酸酶联合外涂几丁糖、局部外涂生理盐水、局部注射生理盐水和不进行任何处理(模型对照组).观察各组大鼠外渗性皮肤损伤发生率、损伤程度和损伤愈合时间.结果:透明质酸酶组和透明质酸酶联合几丁糖组的损伤发生率分别为30%和20%,显著低于几丁糖组、生理盐水外涂组、生理盐水注射组和模型对照组的损伤发生率(90%、100%、90%、100%)(P＜0.05).透明质酸酶组和透明质酸酶联合几丁糖组的损伤愈合时间为(12.00±3.00)天和(9.50±2.12)天,显著短于其它4组(P＜0.01).几丁糖组的损伤愈合时间为(18.33±2.00)天,显著短于生理盐水外涂组[(23.70±2.41)]天和模型对照组[(25.70±2.26)天](P＜0.01).结论:透明质酸酶单独局部注射或联合几丁糖外涂均可减少多西紫杉醇外渗性损伤的发生,缩短损伤愈合时间.单用几丁糖外涂不能防止损伤的发生,却可促进损伤愈合.     

透明质酸酶、地塞米松对长春瑞滨外渗性大鼠皮肤损伤的疗效

 目的　探讨透明质酸酶、地塞米松局部注射对长春瑞滨外渗性大鼠皮肤损伤的防治效果。方法　在40只SD大鼠双后肢制作长春瑞滨血管外渗模型。随机分为5组,分别给予透明质酸酶局部注射、地塞米松局部注射、透明质酸酶联合地塞米松局部注射、0.9 %氯化钠溶液局部注射,模型对照组不进行任何防治措施。观察各组大鼠1、4、8、12、18、24、30 d的损伤面积和损伤愈合时间。结果　透明质酸酶组、地塞米松组、透明质酸酶联合地塞米松组、氯化钠溶液组1、4、8、12、18、24 d损伤面积均显著低于模型对照组（P＜0.05）,其中透明质酸酶组和透明质酸酶联合地塞米松组分别显著低于地塞米松组和氯化钠组（P＜0.05）;透明质酸酶组、地塞米松组、透明质酸酶联合地塞米松组、氯化钠溶液组的损伤愈合时间[（28.8±3.5）d、（28.0±2.9）d、（28.6±4.1）d、（29.8±2.6）d],显著低于模型对照组的（30.6±3.0）d,（P＜0.05）,其中透明质酸酶组和透明质酸酶联合地塞米松组的损伤愈合时间分别显著低于地塞米松组和氯化钠溶液组（P＜0.05）。结论　单用透明质酸酶、地塞米松或0.9 %氯化钠溶液局部注射对长春瑞滨外渗性损伤均有一定的疗效,而透明质酸酶的疗效较好;联合用药可能更有效。     

芦荟凝胶对大鼠多柔比星外渗性损伤的影响

背景与目的:芦荟对多种化疗药物外渗性损伤有良好的防护作用.本实验主要研究芦荟凝胶对大鼠多柔比星外渗性损伤的防治作用,初步探讨芦荟凝胶促进大鼠多柔比星外渗性损伤伤口愈合的机制.方法:建立SD大鼠多柔比星外渗性损伤动物模型,将30只SD大鼠采用自身对照法随机分组:对照组(生理盐水)、实验组(芦荟凝胶l g/L)和硫酸镁组(50%硫酸镁湿敷),测量各组大鼠外渗性损伤的面积,观察损伤程度;在治疗后第1、4、7、11、18天各组分别随机取2只大鼠,切除损伤组织,HE染色观察病理形态学改变.另取30只外渗性损伤模型大鼠随机分组,分组同上.于损伤后第5天切除外渗损伤部位的皮肤及皮下组织,间断缝合,术后第7天拆线,观察手术伤口I期愈合情况和愈合时间.用免疫组化法检测损伤部位的皮肤及皮下组织中的血管内皮生长因子(vascular endothelial growth factor,VEGF)、表皮生长因子受体(epidermal growth factor receptor.EGFR)的表达情况.结果:芦荟凝胶组和硫酸镁组的外渗性损伤面积及程度明显低于生理盐水组(P<0.01).对照组、芦荟凝胶组和硫酸镁组的手术伤口I期愈合率分别为20.0%、60.0%和66.7%.伤口愈合时间分别为(12.1±2.1)d、(9.6±1.6)d和(9.3±1.4)d,对照组与另外两组之间的差异均有统计学意义(P<0.01).免疫组化检测结果显示,芦荟凝胶组与生理盐水组比较,VEGF、EGFR的表达呈现上调.结论:芦荟凝胶对大鼠多柔比星外渗性损伤有良好的防治作用,其促进伤口愈合的机制可能与组织中VEGF、EGFR的表达上调有关.     

磷酸肌酸对阿霉素引起的大鼠心脏毒性的预防保护作用

目的：探讨磷酸肌酸对大鼠阿霉素心脏毒性的保护作用及其作用机制。方法：将SD大鼠随机分为3组,每组10只。生理盐水对照组：每天腹腔注射与阿霉素等量的生理盐水;阿霉素组：实验中前3天每天腹腔注射生理盐水,第4天开始在腹腔注射生理盐水后30分钟给予阿霉素（3mg.kg-1）,隔日1次,共给药7次;磷酸肌酸钠联合阿霉素组：实验中前3天每天腹腔注射磷酸肌酸钠（200mg.kg-1）,第4天开始给予磷酸肌酸钠30分钟后腹腔注射阿霉素（3mg.kg-1）,隔日1次,共给药7次。处死大鼠后作HE染色,光镜下观察各组大鼠心肌病理形态学变化,分别测定大鼠血清、心肌组织中丙二醛（MDA）含量、超氧化物岐化酶（SOD）、谷胱甘肽过氧化物酶（GSH-PX）活性变化。结果：与生理盐水对照组大鼠比较,阿霉素组大鼠血清、心肌MDA含量都显著升高,而SOD、GSH-PX活性均降低（P〈0.05）。给予磷酸肌酸钠治疗后明显降低了血清、心肌组织中MDA含量,增加了SOD、GSH-PX活性,与阿霉素组相比有统计学意义（P〈0.01）。光镜下观察HE染色的阿霉素组心肌组织结构损伤明显,而磷酸肌酸钠联合阿霉素组心肌细胞结构破坏减轻。结论：磷酸肌酸对阿霉素引起的心肌损伤具有保护作用,其作用机制可能与磷酸肌酸能有效改善心肌能量代谢,减少氧自由基引起的心肌氧化性损害、保护抗氧化酶SOD、GSH-PX活性有关。     

芦荟对多柔比星外渗性损伤大鼠创面组织CD105和ICAM-1及VEGF影响的观察

目的:初步探讨芦荟促进大鼠多柔比星外渗性损伤创面愈合的机制.方法:将45只多柔比星外渗性损伤模型大鼠随机分为生理盐水组(1 mL/kg)、硫酸镁组(1 mL/kg)和芦荟组(2.5 g/kg),每组15只,各组用药后第5天切除外渗性损伤部位的皮肤及皮下组织,间断缝合,术后第7天拆线,观察手术伤口Ⅰ期愈合情况和愈合时间.免疫组化法检测损伤部位的皮肤及皮下组织中的CD105、细胞黏附分子-1(ICAM-1)和血管内皮生长因子(VEGF)的表达情况.结果:三组大鼠的手术伤口Ⅰ期愈合率分别为33.3%、73.3%和86.7%,伤口愈合时间分别为(24.5±4.9)、(15.8±3.6)和(14.0±3.5) d,生理盐水组与另外两组之间,差异均有统计学意义,P<0.05.免疫组化结果显示,芦荟组与生理盐水组比较,VEGF、CD105的表达呈现上调,而ICAM-1的表达呈现下调.结论:芦荟能够显著促进外渗性伤口愈合,其作用机制可能与其促进VEGF、CD105的表达和抑制ICAM-1的表达有关.     

芦荟凝胶促进多柔比星外渗性损伤修复及其机制的探讨

目的:初步探讨芦荟凝胶促进大鼠多柔比星外渗性损伤创面的愈合及其机制。方法:将45只多柔比星外渗性损伤模型大鼠随机分为生理盐水组(1mL/kg)、硫酸镁组(1mL/kg)和芦荟凝胶组(2.5g/kg),比较各组大鼠损伤程度及愈合率,ELISA方法检测各组大鼠在处理后1、4、7、11和18d损伤创面中TNF-α、IL-1β和IL-8的含量。结果:处理后18d3组愈合率分别为(38.20±7.10)%、(63.76±17.24)%和(65.84±16.21)%,芦荟凝胶能有效减轻外渗性创面损伤程度,P<0.05。ELISA方法显示,处理后18d两组TNF-α、IL-1β及IL-8含量分别为(14.55±3.13)、(19.63±4.56)ng/L,(9.86±2.78)、(13.81±2.57)ng/L,(5.56±1.46)、(9.01±4.05)ng/L,芦荟凝胶组与生理盐水组比较,TNF-α、IL-1β及IL-8含量明显降低,P<0.05。结论:芦荟凝胶能够显著减轻大鼠多柔比星外渗性损伤创面的损伤程度,促进愈合,其作用机制可能与其降低TNF-α、IL-1β及IL-8的含量有关。     

不同途径给予含血管内皮抑素基因的重组质粒的抑瘤作用研究

目的：比较局部注射和肝动脉灌注含内皮抑素基因的重组质粒抑制大鼠肝癌生长的差异。方法：将肝癌大鼠分为局部注射对照组、肝动脉灌注对照组、局部基因治疗组、肝动脉基因治疗组4组。分别给予200μl生理盐水及200出质粒与脂质体的混合物（含20μg基因）。结果：2个对照组之间的各项指标均未见到统计学差异，（P〉0．05）。局部基因治疗组的抑瘤效果最为明显，与对照组相比（P〈0．05）。而且与肝动脉治疗组相比，在肿瘤体积增长率、生存时间、AI、VEGF表达率方面相比均具有统计学差异，[P〈（0．05—0．01）]。肝动脉治疗组与肝动脉对照组相比，只有肺转移灶、AI具有统计学差异。结论：由于肝动脉给予基因药物受到血液容量、血液成分及脂质体转运效率影响，其抑瘤效果明显低于局部基因注射治疗组的抑瘤效果。采用正确的途径是影响基因治疗肿瘤的关键。     

任意皮瓣局部注射VEGF对其抗菌力影响的实验研究

目的：探讨血管内皮生长因子（VEGF）对皮瓣抗菌力的影响。方法：选用60只SD大鼠,制作背部6×4cm任意皮瓣的动物模型。术中VEGF组局部注射VEGF 1.0μg/瓣,对照组注射等量生理盐水。术后即刻注射绿脓杆菌。结果：碱性成纤维细胞生长因子（bFGF）的测定：术后第3天皮瓣VEGF组bFGF阳性细胞数较生理盐水对照组相应部位有显著增加,差异有显著意义（P〈0.01）。琥珀酸脱氢酶（SDH）：术后第4天VEGF组中段和远段皮瓣SDH活力明显高于生理盐水对照组相应部位,差异有显著意义（P〈0.01）。电镜观察见VEGF组成纤维细胞和血管内皮细胞形态和功能较生理盐水对照组好。术后第11天IL-1β阳性细胞数VEGF组皮瓣较生理盐水对照组皮瓣低,差异有显著意义（P〈0.01）。皮瓣在100低倍镜视野计算血管密度VEGF组较生理盐水对照组高,差异有显著意义（P〈0.01）。结论：VEGF能改善皮瓣微循环、促进血管再生,有明显的促进任意皮瓣成活、抗感染作用。     

多西紫杉醇联合奥沙利铂治疗晚期非小细胞肺癌的临床观察

目的：研究多西紫杉醇加奥沙利铂治疗晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）的近期疗效、毒副反应及神经毒性。方法：96例晚期NSCLC随机分为两组。治疗组49例，多西紫杉醇75mg／m^2静脉滴入，d1；奥沙利铂130mg／m^2，静脉滴入，d2；每3周重复疗程。对照组47例，多西紫杉醇用法及用量同治疗组，顺铂25mg／m^2，静脉滴入，d2～d4，每3周重复疗程。分别评价近期疗效、KPS评分变化、中位生存期、1年生存率、不良反应和神经毒性。结果：治疗组与对照组近期有效率分别为38．78％和36．17％，P=0．788，KPS评分改善率分别为48．98％和34．05％，P=0．138，中位生存期分别为11．5个月和10．3个月，1年生存率分别为42．86％和40．43％（P=0．809），神经毒性发生率分别为20．41％和23．40％，P=0．706；其他不良反应包括中性粒细胞减少、恶心呕吐及疲劳等，治疗组明显低于对照组，P〈O．001。结论：多西紫杉醇加奥沙利铂治疗晚期NSCLC相比多西紫杉醇加顺铂方案疗效相似，但不良反应减少。多西紫杉醇可以明显减轻奥沙刹铂的神经毒性。     

Intraoperative topical tetracycline sclerotherapy following mastectomy: a prospective, randomized trial

BACKGROUND AND OBJECTIVES: Postoperative wound seromas are a frequent and troublesome occurrence after mastectomy. Recent reports have suggested the efficacy of topical sclerosants at reducing their formation. METHODS: A prospective, randomized, double-blinded trial was performed to examine the effect of intraoperatively administered topical tetracycline on the occurrence of postoperative mastectomy seromas. Thirty-two women were randomized to the control arm (normal saline) and 30 women to the tetracycline arm. In the treatment group, 100 ml (2 g) of tetracycline solution was administered topically to the chest wall and skin flaps prior to skin closure. The control group received an equal volume of normal saline. Patients were monitored for the development of postoperative wound seroma. RESULTS: There were no significant differences between groups regarding total volume of closed suction drainage, numbers of patients leaving hospital with drains in place, or duration of catheter drainage. Seroma formation 2 weeks postoperatively was greater in the tetracycline group than the control group (53% vs. 22%, P = 0.01). There were no differences between groups regarding the degree of postoperative pain, wound infection, or seroma formation 1 month postoperatively. CONCLUSIONS: Topical tetracycline is not effective at preventing post-mastectomy wound seromas.     

培美曲塞联合顺铂与多西他赛联合顺铂治疗晚期非小细胞肺癌的疗效比较

目的比较培美曲塞联合顺铂与多西他赛联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效及毒副反应。方法选择我科收治的Ⅲb/Ⅳ期非小细胞肺癌患者60例,采用同期对照研究,随机分为观察组和对照组,每组30例。观察组:培养曲塞500 mg.m-2静滴,d1,顺铂25 mg.m-2静滴,d1～3;对照组:多西地赛75 mg.m-2静滴,d1,8,顺铂25 mg.m-2静滴,d1～3。每3周为1周期重复。每2周期评价疗效,直至疾病进展。结果 60例患者均可评价疗效,观察组总有效率为15.6%,疾病控制率为42.3%,中位生存期为8.9个月,1 a生存率为26.7%;对照组总有效率为13.3%,疾病控制率为40.0%,中位生存期为8.2个月,1 a生存率为23.3%,2组比较差异均无统计学意义(P均>0.05)。观察组骨髓抑制、胃肠道反应、肝功能损害等毒副反应显著低于对照组(P均<0.05)。结论培美曲塞联合顺铂治疗晚期NSCLC的疗效与多西他赛联合顺铂的疗效相近,但毒副反应明显减少,可作为晚期NSCLC患者的一线治疗用药。     

Extravasation of chemotherapeutic agents: prevention and treatment

Most chemotherapeutic agents can cause varying degrees of local tissue injuries when extravasated. The medical treatment of extravasation is based on proper maintenance of the intravenous (IV) line and application of cold or warm compresses, plus the use of antidotes when available. Antidotes for extravasation that have been shown to be useful are sodium thiosulfate for nitrogen mustard, dimethylsulfoxide for anthracyclines and mitomycin, and hyaluronidase for the vinca alkaloids. New treatments include dexrazoxane, sargramostim, and hyperbaric oxygen for doxorubicin extravasations. Tissue damage secondary to drug infiltration occurs as a result of one of two major mechanisms: (1) the drug is absorbed by local cells in the tissue and binds to critical structures (eg, DNA, microtubules), causing cell death; and (2) the drug does not bind to cellular DNA. Damage to immediately adjacent tissue is more readily neutralized than is damage to surrounding tissue.     

Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.

BACKGROUND: In the current study the authors examined the pharmacokinetics of direct intralesional injection of cisplatin/epinephrine/bovine collagen gel in patients with hepatocellular carcinoma and cirrhosis. METHODS: Six patients with cirrhosis and unresectable hepatocellular carcinoma received a direct intralesional injection (range, 6.7-26.7 mg) into their tumors under ultrasonographic guidance. The authors determined the total cisplatin (Pt) concentration in the plasma and urine and nonprotein-bound free Pt in plasma ultrafiltrate using flameless atomic absorption spectrometry. Data from individual patients were analyzed to calculate the pharmacokinetic parameters via a noncompartmental method for constant infusion. To demonstrate that the changes in pharmacokinetics are not related to the underlying cirrhosis, a similar methodology was applied to measure the pharmacokinetic parameters of four similar patients who were treated with cisplatin, 75 mg/m(2), as a 1-hour intravenous infusion. RESULTS: The time to attain maximum concentration of total Pt after intralesional injection was dose-dependent and ranged from 2-13 hours. The concentration-time curve was biphasic in nature. The initial half-life of total Pt in patients who received an intralesional injection varied with the cisplatin dose. The initial half-life for cisplatin doses < 15 mg was approximately 9 hours and the initial half-life at higher cisplatin doses (> 15 mg) was approximately 25 hours. The area under the curve (AUC) was dose-dependent with values ranging from 38-150 microm/mL x hour. Pharmacokinetic parameters for free Pt (ultrafiltrate) were significantly different. The time to attain maximum concentration (t-max) and terminal half-life were shorter and the average AUC was approximately 100-fold lower than total Pt. After the intravenous infusion of cisplatin, the t-max for total and free Pt was 1.3 hours and 1.1 hours, respectively. The terminal half-life and average AUC for total Pt was 194 hours and 247 microg/mL per hour, respectively, and its corresponding parameters for free Pt after intravenous infusion were much lower, similar to the findings for the intralesional injection. CONCLUSIONS: The prolonged t-max and initial half-life noted with the intralesional injection of cisplatin/epinephrine/collagen gel are consistent with its proclaimed ability to retain cisplatin at the tumor and delay its release in systemic circulation. The kinetics of intralesional cisplatin injection also suggest local sequestration of the drug in the injected site. Parameters of intravenous cisplatin infusion in cirrhotic patients are similar to those of patients from the historic control group.     

沙利度胺联合化疗治疗骨转移去势抵抗性前列腺癌的疗效观察

背景与目的:多西他赛联合泼尼松治疗可延长转移性去势抵抗性前列腺癌患者的生存期,血管生成抑制剂也可抑制肿瘤生长,联合治疗的疗效目前仍不明确.该研究旨在观察沙利度胺联合多西他赛和泼尼松治疗骨转移的去势抵抗性前列腺癌的近期临床疗效.方法:收集2008年12月—2015年6月南京军区福州总医院收治的骨转移去势抵抗性前列腺癌患者78例,其中40例作为对照组给予多西他赛和泼尼松方案化疗,38例作为观察组在对照组的基础上给予沙利度胺联合化疗,观察两组有效率、骨痛缓解率、前列腺特异性抗原(prostate specific antigen,PSA)无进展时间、无疾病进展时间及总生存时间,并评价不良反应.结果:观察组有效率为65.79%,PSA无进展时间为4.13个月,无疾病进展时间为4.25个月,骨痛缓解率为86.84%;对照组有效率为40.00%,PSA无进展时间为3.54个月,无疾病进展时间为3.75个月,骨痛缓解率为60.00%,观察组均高于对照组,差异有统计学意义(P<0.05).治疗后两组总生存时间、患者恶心呕吐及白细胞下降等不良反应发生率比较,差异无统计学意义(P>0.05).结论:沙利度胺联合化疗治疗骨转移的去势抵抗性前列腺癌近期临床效果满意,安全,不增加不良反应,具有较高的临床应用价值.     

二甲双胍联合多西他赛对乳腺癌细胞MDA-MB-231增殖和凋亡的影响

目的:通过二甲双胍联合多西他赛观察对乳腺癌细胞MDA-MB-231增殖和凋亡的抑制作用。方法:实验分为4组:多西他赛联合二甲双胍组、单用多西他赛组、单用二甲双胍组以及空白对照组。平板克隆实验检测多西他赛联合二甲双胍对MDA-MB-231细胞克隆形成能力的影响,MTT实验检测多西他赛联合二甲双胍对MDA-MB-231细胞克增殖能力的影响,流式细胞仪检测多西他赛联合二甲双胍对MDA-MB-231细胞凋亡能力的影响。结果:平板克隆实验、MTT实验和流式细胞仪凋亡检测实验结果分别显示:多西他赛联合二甲双胍中细胞的克隆率、增殖能力下降高于单用多西他赛组、单用二甲双胍组以及空白对照组（P<0.05）,而凋亡率多西他赛联合二甲双胍组亦高于其它各对照组（P<0.05）。结论:二甲双胍联合多西他赛能够显著降低乳腺癌细胞MDA-MB-231的克隆和增殖能力,同时增加MDA-MB-231的凋亡能力,两者的联合具有协同杀伤肿瘤细胞的作用。     

Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream

There are limited treatment options for metastatic melanoma, which is almost universally fatal. We report the successful treatment of 64 of 64 cutaneous and subcutaneous melanoma metastases in three patients using high-dose (22 million units per 1.2 ml) intralesional interleukin 2 (IL-2) in combination with topical imiquimod and a retinoid cream. Before intralesional therapy, all patients had been treated surgically and were no longer considered surgical candidates. Rebiopsy of 15 of the treatment sites and long-term follow-up (10, 12, and 27 months) showed regression of all treated tumors. Six months after discontinuation of therapy, one patient developed multiple new cutaneous metastases, but these were also responsive to treatment with intralesional therapy. The other two patients did not experience recurrence of their cutaneous melanoma. However, one of the two patients developed lymph node and brain metastases 18 months after initiation of intralesional therapy, but is still alive, now at 27 months. The concentration of IL-2 used for the intralesional therapy was much higher than in previously reported cases, which may explain the excellent responses that were observed. These results support intralesional high-dose IL-2 as a very effective therapy for controlling cutaneous metastatic melanoma. Additional studies are needed to determine whether this therapy is associated with a survival benefit.     

恩度联合吉西他滨、多西他赛治疗晚期软组织肉瘤的疗效及安全性

目的:探讨恩度联合吉西他滨、多西他赛(GD)治疗晚期软组织肉瘤的疗效及安全性。方法:选取2013年1月至2016年4月入住我院晚期软组织肉瘤患者49例，随机分为恩度组（恩度联合吉西他滨、多西他赛）和对照组（吉西他滨联合多西他赛），比较两组患者疾病控制率、客观缓解率、不良反应及无进展生存期。结果:恩度组疾病控制率为52.17%，高于对照组的23.08%，经χ2检验差异有统计学意义（P<0.05）；两组客观缓解率分别为17.39%和3.85%，差异无统计学意义（P>0.05）；两组患者Ⅲ、Ⅳ度不良反应差异均无统计学意义（P＞0.05）。恩度组无进展生存期为（4.08±0.70）月，对照组为（2.35±0.29）月，差异有统计学意义（P<0.05）。结论:恩度联合GD方案对晚期软组织肉瘤疗效较GD方案好，患者耐受性好，可考虑应用于晚期软组织肉瘤患者。